Skip to main content
PLOS One logoLink to PLOS One
. 2026 Apr 17;21(4):e0346580. doi: 10.1371/journal.pone.0346580

Diagnostic testing intensity for Legionnaires’ disease: Spatio-temporal assessment and its effect on surveillance case reporting, Denmark, 2014–2022

Emmanuel Robesyn 1,2,3,4,*, Søren Anker Uldum 4,5, Karsten Dalsgaard Bjerre 6, Charlotte Kjelsø 2, Marc Struelens 7, Cecilia Stålsby Lundborg 1, Steen Ethelberg 2, Christel Faes 8
Editor: Marta Palusinska-Szysz9
PMCID: PMC13089883  PMID: 41996520

Abstract

Background

The global, national and subnational geographical and temporal distribution of reported Legionnaires’ disease is extremely heterogeneous, and it is unknown to what extent this accurately reflects the variation in true disease incidence. We studied how diagnostic testing intensity varied across Danish municipalities between 2014 and 2022, how it influenced epidemiological surveillance, and how testing-adjusted reporting can be used to improve the study of disease incidence and its determinants.

Methods and findings

We used data from the clinical Danish Microbiology Database and the Epidemiological Surveillance System and considered a tentative causal model of how Legionella infections give rise to the observed Legionnaires’ disease surveillance data. We fitted spatio-temporal models using an approximate Bayesian inference for latent Gaussian models (INLA), providing probabilistic estimates. These allowed us to identify areas of increased risk and spatio-temporal interaction. Our assessment of the Legionnaires’ disease testing intensity in Denmark showed considerable spatio-temporal variation across the country. The estimated municipal annual testing intensity ranged from 128 to 2,446 persons receiving at least one Legionella urinary antigen or PCR test per 100,000 inhabitants. The median increased between 2014 and 2022 steadily from 275 to 620 tested persons per 100,000 inhabitants, reflecting an upward trend. The proportion of tested persons with age over 70 increased from 44.8% to 56.4%. Increasing testing intensity leads to higher case reporting, until testing intensity reaches approximately 1000–1200 tested persons per 100 000 inhabitants. The estimated municipal annual testing-adjusted case reporting ranged from 1.4 to 12.0 per 100 000 inhabitants. The median fluctuated over the study period between 2.5 (range 1.4–6.2) in 2014 and 5.2 (range 1.5–11.7) in 2022 with a flat overall time effect.

Conclusions

We obtained estimates of the spatio-temporal variation of Legionnaires’ disease among Danish municipalities. We quantified the positive effect of testing intensity on Legionnaires’ disease reporting and found a threshold of annually testing slightly over 1% of the population above which the yield of new cases does not further increase. Despite limitations and possible bias, our study of testing-adjusted case reporting suggests that no substantial increase in Legionnaires’ disease has occurred over the nine-year study period. Instead, case ascertainment by physicians has improved considerably through increased Legionella testing, particularly in elderly patients. Insight in the variation of testing intensity and its effect on Legionnaires’ disease reporting can be used to improve guidance for Legionnaires’ disease diagnosis, to better study determinants of Legionnaires’ disease, and ultimately to improve Legionnaires’ disease prevention and control.

Introduction

Since the outbreak in the Bellevue-Stratford Hotel in Philadelphia, 1976 [1], Legionnaires’ disease (LD) – or pneumonia caused by Legionella – has retained, up to today, the attention of public health authorities. Its causative agent elicits sporadic infections, clusters, and outbreaks on all continents. However, the geographical and temporal distribution of the reported disease is extremely heterogeneous, and it is unknown to what extent this accurately reflects the variation in true disease incidence.

Despite the global occurrence [2], the clinical severity [3], the public health burden (mostly attributable to years of life lost [4,5]), and the treatable and preventable character of this waterborne respiratory disease, many low- and middle-income countries have no effective surveillance in place. Also, in high income countries, including within the EU/EEA, public health authorities register widely varying incidence figures, likely reflecting varying degrees of surveillance quality [6]. This is despite a common EU case definition [7,8] and similar national reporting mechanisms (mandatory notification by physicians and clinical laboratories). In Denmark, the reporting incidence increased from 2.2 per 100,000 inhabitants in 2011–2014 [9], to around 4.2 per 100,000 inhabitants in 2019–2022 [10]. With this, Denmark is in the top three of the EU countries with highest Legionnaires’ disease incidence, along with Slovenia and Italy [11]. As in several other countries [12,13], within-country variation has also been studied in Denmark. In a Danish study, a geographical grid model was built to detect areas of excess disease incidence [14]. Another study assessed Danish surveillance data and concluded that age and sex distribution could not explain variation in provincial reporting incidence [15]. Uldum et al. have put forward the hypothesis that a combination of factors influences the incidence rate of LD in each city, including sequence type and serogroup, colonization rate, and concentration of Legionella in water systems [16].

About one per one to two thousand adults per year are thought to suffer from community acquired pneumonia (CAP) [2,17]. It is widely believed that of the CAP caused by Legionella, many remain undiagnosed. To account for this underascertainment and estimate the true Legionnaires’ disease incidence, etiological studies of CAP aim to provide the proportion of CAP attributable to Legionella infection to assign multiplication factors. A systematic review and meta-analysis estimated that around 4.6% of the CAP is caused by Legionella [2,18].

As a consequence of under- or misdiagnosis, Legionnaires’ disease is often inadequately treated [19]. Furthermore, the lack of etiological diagnosis entails missed opportunities to identify the source of infection and implement preventive action [20]. Although Legionnaires’ disease has a number of clinical features that are distinct from other causes of pneumonia [21,22], the diagnosis requires a microbiological test [23,24], as reflected in surveillance case definitions [7] and clinical diagnostic guidelines [25].

The importance of testing intensity to interpret changes in infectious disease reporting has been recognized previously [2628]. In the Netherlands a study excluded a change in diagnostic intensity as cause of decline in reported Legionnaires’ disease cases [29]. Authors of a scoping review, concluded that increased testing for Legionella and improved diagnostics may be a driver with moderate impact on increasing incidence [30].

Several studies have also assessed factors related to the diagnostic testing for Legionnaires’ disease. The test availability has been highlighted as condition for appropriate diagnosis [3133]. A Swiss study described an increase in tests at provincial level and found that the guidelines, the diagnostic value of the test, and financial and time considerations, were factors influencing the use of tests [34]. In relation to the timing of testing, Allgaier reported that despite more than two thirds (70%) of positive test results happened between June and October, only about a third (36%) of the tests took place in these months, and called for guidelines to support routine Legionella testing [35].

Furthermore, the type of diagnostic tests used is relevant for the observed disease incidence. In Denmark, routine laboratory diagnosis mainly relies on three methods: the urinary antigen test (UAT), which primarily detects L. pneumophila serogroup 1 [24,36,37], PCR targeting L. pneumophila [38,39], and broader PCR targeting Legionella spp. [24,38]. These methods differ in diagnostic scope and performance and therefore in case ascertainment [24,40,41]. For example, UAT detects primarily L.pneumophila SG1, which represented in 2023 in Denmark only 63.4% of culture-confirmed cases [10]. Although Denmark is renowned for its high proportion of bacterial culture confirmation (35.1% of cases in 2023) [10], which is the gold-standard for Legionella typing and source-attribution, culture alone does not contribute to the population testing intensity as it is always combined with other tests.

Diagnostic guidelines describing for which patients to request microbiological Legionella tests do not only matter for individual patient care. They also affect the sensitivity and specificity of surveillance systems based on mandatory notification of clinically diagnosed cases, as for Legionnaires’ disease [19].

The other way around, surveillance is relevant for individual medical decision making, as well as for the development of diagnostic guidelines. For doctors to assess the positive and negative predictive value of a test result, they need to have an accurate sense of the disease incidence, for which they rely, knowingly or not, on surveillance data. For drafting clinical guidelines, Woodhead pointed in an editorial back in 2002 at the importance of geographical variation in the pathogen occurrence and other factors. Guidelines may not be relevant to all countries equally [37] and pathogen distribution does not follow national boundaries [17], highlighting the importance of (sub)national incidence estimation. Additionally, together with risk management of pathogenic Legionella species in engineered water systems, both the diagnostic guidelines and surveillance are essential for disease prevention. Indeed, detection of cases is needed to identify the environmental hazards that cause them [42].

Currently, in most countries, public health authorities still have limited access to data about diagnostic testing for infectious diseases. This makes it challenging to measure diagnostic testing intensity comprehensively or estimate it for surveillance purposes, and if used, e.g., during the COVID-19 pandemic, often “changes in testing policies ... could not be accounted for and rendered surveillance data poorly comparable” [4345].

In this study, we intended to assess how diagnostic testing intensity influences the case reporting of Legionnaires’ disease, and how data on testing intensity can be used to better learn about the underlying disease incidence. We aimed to provide a justification and methodology for use of comprehensive data on diagnostic testing intensity, or estimates thereof, to better interpret surveillance results and to improve research towards Legionnaires’ disease determinants. This in turn is expected to improve prevention and control of the disease.

Materials and methods

a) Scientific model and assumptions

Our estimated quantities and effect are based on a number of causal assumptions, as expressed in a directed acyclic graph (DAG)(Fig 1) [46,47]. We assume that geographical units (municipalities) differ among each other and vary over time in their population size, age- and sex-distribution, and environmental and behavioural determinants of diverse causes of pneumonia, such as Legionnaires’ disease and other types of pneumonia. This results in varying levels of, unmeasurable, Legionnaires’ disease incidence, which we aim to estimate from surveillance data. In the present study, also the determinants are not measured, except for the demographic characteristics of the areas.

Fig 1. Directed Acyclic Graph (DAG) and direct effect on case reporting (estimand = green arrows, Leg = Legionella spp. or L.pneumophila, LD = Legionnaires’ disease).

Fig 1

For an individual to be counted as a Legionnaires’ disease case, the case definition requires the case to present with pneumonia and have been tested, and the Legionella test to be positive. As a consequence, at the population level, both a change in the disease incidence and a change in the testing intensity level may influence the reported case count. The latter is especially true in the presence of underascertainment.

The DAG further expresses our believe that, at population level, the volume of diagnostic Legionella testing is not merely a consequence of people having Legionnaires’ disease, consulting a physician and receiving a diagnostic test. Instead, due to the aspecificity of Legionnaires’ disease symptoms, we assume that the Legionella testing intensity is also (and to a larger extent) driven by the much larger volume of non-Legionella pneumonia, mainly community acquired pneumonia (CAP), and the clinicians’ inclination to test CAP patients for Legionella. This assumption is supported by the higher volume of testing (Table 1, Table 2) and the more similar seasonality to non-LD CAP than to Legionnaires’ disease (S2 Fig 4 in S1 Appendix) [48,49]. The effect of age and sex on Legionnaires’ disease has been widely reported [23].

Table 1. Tested persons (n = 257 726) by age group, sex or province, and by year.

2014 (N = 16970) 2015 (N = 21541) 2016 (N = 25221) 2017 (N = 26187) 2018 (N = 29359) 2019 (N = 28285) 2020 (N = 31327) 2021 (N = 37955) 2022 (N = 40881)
Age group
 00-49 3121 (18.4%) 4492 (20.9%) 5732 (22.7%) 5175 (19.8%) 4968 (16.9%) 5013 (17.7%) 4948 (15.8%) 6289 (16.6%) 6468 (15.8%)
 50-59 2265 (13.3%) 2781 (12.9%) 3261 (12.9%) 3237 (12.4%) 3545 (12.1%) 3456 (12.2%) 3614 (11.5%) 4114 (10.8%) 4191 (10.3%)
 60-69 3982 (23.5%) 4772 (22.2%) 5251 (20.8%) 5305 (20.3%) 5974 (20.3%) 5575 (19.7%) 5780 (18.5%) 6725 (17.7%) 7186 (17.6%)
 70-79 4171 (24.6%) 5393 (25.0%) 6235 (24.7%) 6862 (26.2%) 8140 (27.7%) 7771 (27.5%) 8748 (27.9%) 10347 (27.3%) 11474 (28.1%)
 over 80 y 3431 (20.2%) 4103 (19.0%) 4742 (18.8%) 5608 (21.4%) 6732 (22.9%) 6470 (22.9%) 8237 (26.3%) 10480 (27.6%) 11562 (28.3%)
Sex
 female 7894 (46.5%) 10372 (48.2%) 12255 (48.6%) 12376 (47.3%) 14011 (47.7%) 13433 (47.5%) 14409 (46.0%) 17820 (47.0%) 19697 (48.2%)
 male 9076 (53.5%) 11169 (51.9%) 12966 (51.4%) 13811 (52.7%) 15348 (52.3%) 14852 (52.5%) 16918 (54.0%) 20135 (53.0%) 21184 (51.8%)
Province of residence
 Bornholm 78 (0.5%) 117 (0.5%) 226 (0.9%) 165 (0.6%) 132 (0.4%) 151 (0.5%) 174 (0.6%) 226 (0.6%) 291 (0.7%)
 Copenhagen City 2523 (14.9%) 3531 (16.4%) 4185 (16.6%) 3977 (15.2%) 3842 (13.1%) 4166 (14.7%) 4178 (13.3%) 6333 (16.7%) 6902 (16.9%)
 Copenhagen Surroundings 1345 (7.9%) 1693 (7.9%) 2128 (8.4%) 2479 (9.5%) 3090 (10.5%) 3952 (14.0%) 5462 (17.4%) 6069 (16.0%) 6073 (14.9%)
 East Jutland 1926 (11.3%) 2680 (12.4%) 3387 (13.4%) 3675 (14.0%) 3999 (13.6%) 2853 (10.1%) 2371 (7.6%) 2598 (6.8%) 2902 (7.1%)
 East Zealand 636 (3.7%) 796 (3.7%) 907 (3.6%) 974 (3.7%) 1187 (4.0%) 830 (2.9%) 654 (2.1%) 1091 (2.9%) 1533 (3.8%)
 Funen 2044 (12.0%) 2773 (12.9%) 3106 (12.3%) 3463 (13.2%) 3346 (11.4%) 3870 (13.7%) 5106 (16.3%) 5209 (13.7%) 4548 (11.1%)
 North Jutland 1094 (6.4%) 1323 (6.1%) 1488 (5.9%) 1304 (5.0%) 1368 (4.7%) 1279 (4.5%) 1024 (3.3%) 1043 (2.7%) 1236 (3.0%)
 North Zealand 2357 (13.9%) 2159 (10.0%) 1611 (6.4%) 2155 (8.2%) 2972 (10.1%) 3185 (11.3%) 4101 (13.1%) 4852 (12.8%) 4959 (12.1%)
 South Jutland 2326 (13.7%) 2792 (13.0%) 3411 (13.5%) 3917 (15.0%) 4618 (15.7%) 4516 (16.0%) 5269 (16.8%) 5775 (15.2%) 6926 (16.9%)
 West and South Zealand 1564 (9.2%) 1826 (8.5%) 2199 (8.7%) 2392 (9.1%) 2957 (10.1%) 2091 (7.4%) 1550 (4.9%) 2505 (6.6%) 3060 (7.5%)
 West Jutland 1077 (6.3%) 1851 (8.6%) 2573 (10.2%) 1686 (6.4%) 1848 (6.3%) 1392 (4.9%) 1438 (4.6%) 2254 (5.9%) 2451 (6.0%)

Count (Column Percentage).

Table 2. Reported cases (n = 2081) by age group, sex or province, and by year.

2014 (N = 147) 2015 (N = 174) 2016 (N = 161) 2017 (N = 270) 2018 (N = 258) 2019 (N = 259) 2020 (N = 268) 2021 (N = 270) 2022 (N = 274)
Age group
 00-49 15 (10.2%) 11 (6.3%) 22 (13.7%) 22 (8.1%) 23 (8.9%) 24 (9.3%) 25 (9.3%) 23 (8.5%) 18 (6.6%)
 50-59 29 (19.7%) 25 (14.4%) 30 (18.6%) 53 (19.6%) 46 (17.8%) 37 (14.3%) 41 (15.3%) 38 (14.1%) 24 (8.8%)
 60-69 49 (33.3%) 53 (30.5%) 48 (29.8%) 72 (26.7%) 62 (24.0%) 66 (25.5%) 57 (21.3%) 58 (21.5%) 59 (21.5%)
 70-79 32 (21.8%) 53 (30.5%) 40 (24.8%) 66 (24.4%) 75 (29.1%) 73 (28.2%) 79 (29.5%) 79 (29.3%) 98 (35.8%)
 over 80 y 22 (15.0%) 32 (18.4%) 21 (13.0%) 57 (21.1%) 52 (20.2%) 59 (22.8%) 66 (24.6%) 72 (26.7%) 75 (27.4%)
Sex
 female 57 (38.8%) 60 (34.5%) 60 (37.3%) 103 (38.1%) 90 (34.9%) 103 (39.8%) 114 (42.5%) 105 (38.9%) 114 (41.6%)
 male 90 (61.2%) 114 (65.5%) 101 (62.7%) 167 (61.9%) 168 (65.1%) 156 (60.2%) 154 (57.5%) 165 (61.1%) 160 (58.4%)
Province of residence
 Copenhagen City and Bornholm 16 (10.9%) 11 (6.3%) 17 (10.6%) 12 (4.4%) 17 (6.6%) 16 (6.2%) 9 (3.4%) 35 (13.0%) 36 (13.1%)
 Copenhagen Surroundings 12 (8.2%) 13 (7.5%) 9 (5.6%) 19 (7.0%) 30 (11.6%) 33 (12.7%) 39 (14.6%) 41 (15.2%) 35 (12.8%)
 East Jutland 18 (12.2%) 29 (16.7%) 27 (16.8%) 62 (23.0%) 38 (14.7%) 29 (11.2%) 23 (8.6%) 15 (5.6%) 17 (6.2%)
 East Zealand 7 (4.8%) 12 (6.9%) 5 (3.1%) 12 (4.4%) 17 (6.6%) 12 (4.6%) 13 (4.9%) 13 (4.8%) 17 (6.2%)
 Funen 26 (17.7%) 40 (23.0%) 28 (17.4%) 40 (14.8%) 30 (11.6%) 49 (18.9%) 45 (16.8%) 30 (11.1%) 34 (12.4%)
 North Jutland 13 (8.8%) 8 (4.6%) 17 (10.6%) 16 (5.9%) 18 (7.0%) 16 (6.2%) 18 (6.7%) 18 (6.7%) 13 (4.7%)
 North Zealand 17 (11.6%) 16 (9.2%) 7 (4.3%) 29 (10.7%) 26 (10.1%) 31 (12.0%) 35 (13.1%) 31 (11.5%) 45 (16.4%)
 South Jutland 15 (10.2%) 21 (12.1%) 27 (16.8%) 39 (14.4%) 47 (18.2%) 37 (14.3%) 44 (16.4%) 41 (15.2%) 34 (12.4%)
 West and South Zealand 13 (8.8%) 17 (9.8%) 13 (8.1%) 27 (10.0%) 22 (8.5%) 21 (8.1%) 25 (9.3%) 36 (13.3%) 31 (11.3%)
 West Jutland 10 (6.8%) 7 (4.0%) 11 (6.8%) 14 (5.2%) 13 (5.0%) 15 (5.8%) 17 (6.3%) 10 (3.7%) 12 (4.4%)

Count (Column Percentage).

A difference between the count of persons tested positive for Legionella and persons diagnosed as Legionnaires’ disease can be explained by elements of differential diagnosis other than clinical presentation of pneumonia and the Legionella test result. Such aspects can be symptomatology (e.g., presence or absence of high fever or bradycardia), clinical evolution (e.g., response to initial empirical therapy), blood chemistry values (e.g., presence or absence of hypophosphatemia or hyponatremia), lung radiography, Legionella test type (e.g., PCR Legionella species (Legionella spp.) versus Legionella pneumophila (L.pn.)), sample type (e.g., upper- vs. lower-respiratory tract sample), or likelihood of competing diagnoses (e.g., Chlaymydia or Mycoplasma infection, Q fever, psittacosis).

In principle, the count of diagnosed patients may differ from the count of reported cases due to imperfect compliance to report by physicians and labs. However, this is assumed negligible in Denmark since 2014 due to an automated detection algorithm on the Danish Microbiology Database, whereby for each positive test, the diagnosis is verified with the clinician.

b) Data

The data concerned all Legionella tests performed in Denmark between 2014 and 2022, retrieved from the Danish Microbiology Database (MiBa) [5052]. Age, sex, and municipality of residence from the tested persons originated from the civil registration. Further, the study included data of all Legionnaires’ disease cases reported between 2014 and 2022 to the Department of Infection Epidemiology and Prevention at Statens Serum Institut [53].

Samples and data had been collected as part of routine national Legionnaires’ disease surveillance and were exempt from informed consent procedures. The data (2014–2021) were made available for research purpose as of May 2022, and updated data (to include 2022) as of May 2023. Data were pseudonymized and aggregated for the analysis. No individuals could be identified with the data available to the analyst. According to Danish law, no approval from an ethics committee was required for this surveillance study. This study was performed under the auspices of Statens Serum Institut as per the Danish Health Act, Section 222 [54]. Permission to use the data for this report was granted by Data Protection and Information Security (project J. No. 21/06213, Legionnaires’ disease diagnostics; testing intensity and case reporting for Legionnaires’ disease in Denmark 2014–2022).

The tests included were urinary antigen test for L. pneumophila SG1 (UAT), polymerase chain reaction test for L. pneumophila (PCR L. pneumophila) or PCR for Legionella spp. (PCR Legionella spp.). Tests were performed on urine samples or -upper or lower- respiratory tract samples. We used the testing date, the municipality of residence at the time of the test, sex, and five-year age group at time of test, estimated from mid-year of birth.

Annual tested persons were defined as persons who had received at least one of the three types of Legionella tests in a given year. Some individuals were tested in several years; presumably for different pneumonia episodes. However, a small proportion who were tested at the end and start of a year may have been double-counted while referring to the same disease episode. We defined the within-year test profile as the combination of test types a person received in a given year, and report these for descriptive purpose only.

Cases fulfilled the EU case definition of confirmed or probable case. Throughout the study period, the EU case definition considered a positive urinary antigen test as a confirmed case criterium, and a positive PCR test as a probable case criterium, but this distinction in case classification was not deemed relevant to our study and was therefore not used. The setting of exposure was travel-, healthcare-, or community-associated, all contributing to the total case counts, i.e., without differentiating whether a case may have been infected locally or abroad, in the community or in a hospital, or was part of an outbreak or not. From the cases, we used the reporting date, as well as the sex and five-year age group at time of report. Case location was, as for tested persons, the municipality of residence at time of the (positive) test, retrieved from the microbiology database and the civil registration. Cases for which the location could not be retrieved (102 cases, evenly distributed over the nine study years), were included in the description but excluded for the spatial modeling.

Demographic data about the population by municipality (N = 99), year (9), sex (2), and 5-year age groups (19) were downloaded from Statistics Denmark [55]. We applied indirect standardization based on the entire country and study period as reference to obtain expected counts.

We defined two derived quantities. Diagnostic testing intensity (rate) was defined as the number of annual tested persons per 100,000 inhabitants per year. Case reporting (rate) was defined as the number of cases reported to the Epidemiological Surveillance System per 100,000 inhabitants per year.

c) Statistical model fitting and model comparison

To obtain estimates of diagnostic testing intensity and of case reporting by geographical area and time, we built Bayesian hierarchical spatio-temporal models. We modelled yearly data at municipality level. We used models that allow for partial pooling of municipal data [47,56] as small areas have due to their limited population size typically highly variable standardized incidence ratios (SIR), making these inappropriate for our purpose.

Considering our DAG and estimand, we selected the model’s functional form (not expressed by the DAG) based on the lowest widely applicable information criterion (WAIC) [47,57]. We explored models with a variety of structured and unstructured spatial effects, fixed or varying time effects, and space-time interaction effects. Non-linear effects were modelled as random walk (RW) and autoregressive (AR) processes. Several spatial and spatio-temporal models were compared. All fitted models are listed in supplement (S9, S10 in S1 Appendix).

Models were fitted using Integrated Nested Laplace Approximation, INLA, an approximate Bayesian inference framework for latent Gaussian models [58]. Analyses were performed using R Statistical Software, version 4.4.0 [59] and the R-INLA package [60]. Graphs and maps of the results were created with the R packages ggplot2 version 3.5.1 and tmap version 4.2. The basemap of the Danish municipalities was adapted from OpenStreetMap, available under the Open Database License (https://www.openstreetmap.org/copyright). Computing code for modeling and visualisations from paper and supplement is available at GitHub (https://github.com/erobesyn/dk_testing_reporting) and a permanently archived Zenodo repository (https://doi.org/10.5281/zenodo.15238532).

The best fitting models, both for the diagnostic testing intensity and for the case reporting, have a spatial convolution effect composed of a spatially correlated effect (ICAR) and spatially uncorrelated effect (iid) (as in Besag, York and Molie model) [61,62], a temporal random walk of first order, and an unstructured spatio-temporal interaction (iid). This model is known as type I Knorr-Held model [63].

The model for the estimated count of tested persons (exposure model) is given in equation (A):

Tit~Poisson(μit)
μit=eit rit
log(rit)=α0+ξi+γt+δit

where i represents the municipality and t the year.

The model for the estimated count of reported cases (outcome model) is defined in equation (B):

Cit~Poisson(μit)
μit=eit rit
log(rit)=α0+βT.obsit+ξi+γt+δit

where i represents the municipality and t the year.

Further, eit is the 5-year age group- and sex-standardized expected count, and rit is the relative risk of interest. In the Results section, we call the relative risk from the two models, respectively, the ‘relative testing intensity (RRT)’ and the ‘relative case reporting (RRC)’, i.e., the multiplicative factor for a specific year and municipality as compared to the expected value. A value of two means that the testing intensity or case reporting was twice as large as expected from the overall intensity/reporting in the whole country.

In the model, α0 is an intercept, βT.obsit a varying effect of binned count of tested persons, ξi a spatial varying effect, γt a temporal varying effect, and δit a spatio-temporal interaction effect. The spatial varying effect ξi is composed of a spatially structured and a spatially unstructured effect (S8 in S1 Appendix).

Results

a) Description

In the study period between 2014 and 2022, the Danish population has grown monotonically from 5.63 to 5.87 million inhabitants. Our analysis did not include Greenland and the Faroe Islands, with population sizes in 2022 of 56,661 and 53,952, respectively.

The proportion of Danish people with age over 70 years has increased in our study period from 11.9% to 14.9% (+3 percentage points), while the national population’s sex ratio remained roughly the same with around 49.7% male (S5 Table 2 in S1 Appendix). Bornholm is the province with the smallest population, i.e., 39,638 inhabitants (2022), while East Jutland is the most populated province with 913,861 inhabitants (2022). The median population in 2022 by municipality was 43,089 (IQR 30,332–59,752), ranging from 93 (Christiansoe) to 644,431 (Copenhagen).

Excluding 0.3% of performed tests for which the result was not registered, we included 350 814 tests with positive or negative result and for which age, sex, and municipality of residence of the tested person was known. Of these, 4,752 (1.35%) were positive tests. The yearly number of tests performed in Denmark more than doubled over the study period, from 24,065 tests (2014) to 54,928 tests (2022). The relative proportions of urinary antigen test and PCR changed over time: the proportion UAT decreased from 39% in 2014 to 11% in 2022, while the proportion PCR L. pneumophila increased from 44% to 71%. The proportion PCR Legionella spp. remained stable at around 17%.

257,729 persons were tested for Legionella infection in a given year (annual tested persons), corresponding to 214,807 unique tested persons over the nine-year study period. Of the annual tested persons, 2,634 (1.0%) were found to have tested positive (in one or more of their tests).

The number of annual tested persons grew steadily from 16,970 tested persons (2014) to 40,881 tested persons (2022) (Table 1, and S7 Fig 9 in S1 Appendix). The proportion of tested persons with age over 70 years has increased from 44.8% to 56.4% (+11.6 percentage points). The proportion of tested males fluctuated between 51.4% and 54.0% without clear year trend. The annual number of tested persons per province ranged, in 2022, from 291 (Bornholm) to 6926 (South Jutland) (S7 Fig 10 in S1 Appendix). The median number of tested persons in 2022 by municipality was 305 (IQR 158–498), ranging from less than ten (Christiansoe and Laesoe) to 5142 (Copenhagen).

Furthermore, the annual tested persons can be grouped by their within-year test profile (S6 Table 3 in S1 Appendix). The proportion of tested persons who received, within a given year, only UAT without PCR decreased from 27% in 2014 to 6.2% in 2022. Also, the test profile UAT with PCR Lpn decreased from 17.8% in 2014 to 5.2% in 2022. On the other hand, the proportion of tested persons who received within a given year only PCR Lpn doubled from 33.9% in 2014 to 67.8% in 2022, with the largest increase (+17 percentage points) in 2020, the first year of the COVID-19 pandemic.

In the nine year period, there were 2,183 reported Legionnaires’ disease cases, of which 2,081 with the location data needed for spatial description and modeling. The 2,183 cases correspond to 83% of all positive tested persons in the database. They consist of 63.2% community acquired cases (CALD, n = 1,380), 10.0% healthcare associated cases (HALD, n = 218), 18.8% travel-associated cases (TALD, n = 410), and 8.0% cases for which the setting was not recorded (n = 175).

The number of reported cases with known location has overall grown from 147 cases in 2014 to 274 in 2022, with the largest increase from 2016 to 2017, when 109 extra cases (+68%) were reported (Table 2, and S7 Fig 9 in S1 Appendix). The proportion of reported cases with age over 70 years grew from 36.8% to 63.2% (+26.4 percentage points), however with yearly fluctuations. The proportion male fluctuated between 57.5 and 65.5% without clear trend. The annual number of reported cases per province ranged, in 2022, from well below ten (Bornholm) to 45 (North Zealand) but reached 62 in 2017 in East Jutland (S7 Fig 11 in S1 Appendix). The median number of reported cases in 2022 by municipality was 2 (IQR 1–4); for all municipalities there were less than 10 cases in 2022, except for Frederiksberg, Odense and Copenhagen with respectively 10, 13, and 22 cases.

b) Diagnostic testing intensity

The estimated diagnostic Legionella testing intensity is determined by the age- and sex-standardized relative testing intensity estimated from our model and the population size, and age and sex distribution in a given municipality. Fig 2 shows the map of the testing intensity by year and municipality. The municipal testing intensity ranged from 128 to 2,446 per 100,000 inhabitants. The median municipal testing intensity over the entire nine-years study period was 419 tested persons per 100,000 inhabitants per year (IQR 294–631). The median increased steadily from 275 tested persons per 100,000 inhabitants in 2014 to 620 in both 2021 and 2022. Of the ten lowest testing intensities, nine are from municipalities in North Jutland, mainly in 2014. Since 2020, some municipalities reached testing intensities of over 1,500 per 100,000 inhabitants, i.e., testing 1 in 67 inhabitants in a given year. This was the case in nine municipalities: five in Funen (Kerteminde, Langeland, Nyborg, Svendborg, Faaborg-Midtfyn), three in South Jutland (Vejen, Billund, Esbjerg), and one in Copenhagen Surroundings (Broendby). Among these, the most intensive testing took place in Langeland and Vejen, where more than 1 in 50 inhabitants received at least one of the three Legionella tests in a given year. The testing intensity in Langeland increased gradually to be in 2022 six-fold the level of 2014.

Fig 2. Map of estimated testing intensity, by year and municipality, Denmark 2014-2022.

Fig 2

The estimated age- and sex-standardized relative testing intensity in municipalities (RRT), ranged from 0.18 (Laesoe, North Jutland, 2014) to 4.01 (Vejen, South Jutland, 2022) (S11 Fig 12–13 in S1 Appendix). The highest relative testing intensities, with RRT over 3, were all in 2021 and 2022, either in South Jutland (Vejen, Esbjerg and Billund), Copenhagen Surroundings (Hvidovre) or Funen (Langeland, Nyborg). Twenty-six municipalities had a relative testing intensity over 2. The lowest relative testing intensities, with RRT under 0.33, were in North Jutland (Broenderslev, Frederikshavn, Hjoerring, Laesoe, Morsoe, Rebild, Thisted, Jammerbugt, Mariagerfjord) and South Jutland (Fanoe, 2014 only). Fifty-five municipalities had a relative testing intensity under 0.5.

The variance in relative testing intensities among municipalities can be attributed to different components. The largest component, 55.6% of the variance, is spatially structured variation related to the neighbourhood structure of municipalities, expressing that bordering municipalities are more alike than far away municipalities. Further, 1.0% can be explained by spatially unstructured variation, 5.5% by temporal variation, and 37.9% by spatio-temporal interaction. The structured and unstructured spatial varying effects and spatio-temporal interaction varying effect are shown in the supplementary material (S12 Fig 15, S13 Fig 16 in S1 Appendix).

We distinguish an area with high exceedance probability, Pr(RRT > 1), i.e., where the testing intensity is very likely to be higher than expected (S11 Fig 14 in S1 Appendix). This area covers the majority of Funen, a triangular part of South and West Jutland, and the area of Copenhagen City and Surroundings. Complement to this, we identify Zealand, the south of South Jutland, East Jutland and North Jutland, as areas with a likely deficit in relative testing intensity.

c) Effect of diagnostic testing intensity on case reporting

We estimated that the relative Legionnaires’ disease testing intensity in Denmark has steadily increased over time (Fig 3b). Further, we estimated that with increasing testing intensity, the relative case reporting increased (Fig 3a and S14 Fig 17 in S1 Appendix). The increasing relative case reporting is observed up to about 1000–1200 tested persons per 100 000 inhabitants, with relative case reporting of about 1.7. At higher testing intensities, there is no further improvement in case reporting and there is larger uncertainty of the estimate. The relative Legionnaires’ disease case reporting, when adjusted for the testing intensity, does not increase over time but shows a small dip in 2016, followed by a small peak in 2017 (Fig 3, c).

Fig 3. Effect of diagnostic testing intensity on case reporting, and evolution over time of both.

Fig 3

(a) Effect of testing intensity on relative case reporting, (b) Evolution of relative testing intensity over time, (c) Evolution of relative case reporting, adjusted for testing intensity, over time. Effects (and 95% compatibility interval) on the relative risk scale. Denmark 2014–2022.

d) Case reporting, adjusted for varying testing intensity

We estimated the municipal, annual, testing-adjusted case reporting. The testing-adjusted case reporting ranged from 1.4 (Aarhus, East Jutland, 2021) to 12.0 (Langeland, Funen, 2020) per 100 000 inhabitants. The median over the entire study period and all municipalities was 3.9 reported cases per 100 000 inhabitants (IQR 2.9–5.6). The annual median fluctuated over the study period between 2.5 (range 1.4–6.2) in 2014 and 5.2 (range 1.5–11.7) in 2022 with a flat overall time effect.

Fig 4 shows the evolution of the case reporting both over time and space. In two municipalities the incidence exceeded 11/100 000 in one or more years, namely Langeland (Funen) and Halsnaes (North Zealand). Twelve other municipalities had in one or more years a reporting incidence over 9/100 000, mainly in Funen (Middelfart, Nyborg, Svendborg, Assens, Faaborg-Midtfyn) and North Zealand (Hoersholm, Gribskov, Furesoe, Helsingoer), but also two municipalities in Copenhagen Surroundings (Herlev, Roedoevre) and one in South Jutland (Kolding). Langeland was the municipality with the longest sustained very high Legionnaires’ disease incidence, with seven out of nine years exceeding an incidence of 9/100 000, followed by Nyborg which exceeded this threshold during five years.

Fig 4. Map of estimated case reporting, adjusted for varying testing intensity, by year and municipality, Denmark 2014-2022.

Fig 4

In contrast, Aarhus and Skanderborg (East Jutland) both had less than 1.5 cases per 100 000 inhabitants: for Skanderborg only in 2014, but for Aarhus in 2014 as well as in 2021 and 2022. In 19 other municipalities the adjusted reporting was below 2 per 100 000 inhabitants in at least one year: in the province Bornholm (Bornholm), Copenhagen City (Copenhagen), Copenhagen Surroundings (Albertslund, Gentofte, Gladsaxe), North Jutland (Rebild, Thisted, Vesthimmerlands, Broenderslev), North Zealand (Egedal, Furesoe), East Jutland (Horsens, Odder), East-Zealand (Solroed), South Jutland (Billund, Esbjerg, Varde), and West Jutland (Ikast-Brande, Viborg).

The estimated age- and sex-standardized relative case reporting (RRC), compared to the expected for the nine-year period, adjusted for testing intensity, ranged from 0.38 (Bornholm, Bornholm, 2014) to 2.76 (Roedovre, Copenhagen Surroundings, 2020) (Fig 5). Also, Herlev (Copenhagen Surroundings) had in 2020 more than 2.5 times the expected relative case reporting incidence. The mean relative case reporting exceeded the value of 2 in 2 other municipalities of Copenhagen Surroundings (Gladsaxe, Lyngby-Taarbaek), 5 municipalities of Funen (Assens, Middelfart, Nyborg, Odense, Svendborg), 2 municipalities of North Zealand (Furesoe, Halsnaes), 1 municipality of East Jutland (Randers), and 2 municipalities of South Jutland (Kolding, Vejle). Kolding and Odense were affected for the longest time, in respectively, 5 and 4 of the 9 years.

Fig 5. Map of relative case reporting, adjusted for varying testing intensity, by year and municipality, Denmark 2014-2022.

Fig 5

Twenty-six municipalities had (in least one year) a case reporting less than half the expected value (RRC < 0.5). Of these, the following municipalities had the lowest relative testing-adjusted case reporting (RRC ≈ 0.4): Bornholm (Bornholm), Varde (South Jutland), Skanderborg, Aarhus, Odder (East Jutland), and Vesthimmerlands and Broenderslev (North Jutland).

For the detection of LD clusters, we consider the probability that the relative case reporting is larger than one (Pr(RRC)>1)(Fig 6), i.e., how likely is it that there are more than expected cases, accounting for varying age and sex distribution and varying testing levels across municipalities.

Fig 6. Map of exceedance probability (Pr(RR > 1)) of relative case reporting, adjusted for varying testing intensity, by year and municipality, Denmark 2014-2022.

Fig 6

Thirty-two municipalities had in at least one of the years, with over 95% probability, excess case reporting, compared to the nine-year expected value, and for 18 of these, this was nearly certain (over 99% probability): Odense, Middelfart, Nyborg, Svendborg, Assens, Ballerup, Gladsaxe, Herlev, Lyngby-Taarbaek, Roedovre, Gribskov, Helsingoer, Furesoe, Halsnaes, Randers, Kolding, Fredericia, and Vejle. Sixty-four municipalities had in at least one of the years over 95% probability to have deficit case reporting, and for 34, this was nearly certain (over 99% probability).

The variance in case reporting across the municipalities and years can be attributed to different components: 10.0% can be explained by spatially structured variation, 40.5% by spatially unstructured variation, 7.9% by temporal variation, and 41.6% by spatio-temporal interaction. The structured spatial effect shows strong homogeneity within regions, explained by some spatial similarity among municipalities, which can be environmental (e.g., weather, soil, housing water systems) or related to distribution of certain Legionella sequence types (and their pathogenicity). However, the spatial structured effect contributes proportionally less to the overall variation than we saw for testing intensity. In supplement, the reader will find the maps for these varying effects (S16 Fig 19, S17 Fig 20 in S1 Appendix).

Apart from the spatio-temporal excess relative case reporting, the space-time interaction can be considered a complementary indication of disease clustering in a given area and year [56,64]. Fig 7 shows the probability that such space-time interaction is larger than zero. These are areas and timepoints with high probability that some clustering process has happened beyond the age, sex, and testing adjusted spatio-temporal trend. We found that only in Odense (Fyn) in 2015 the space-time interaction was beyond the expected with a probability over 95%.

Fig 7. Map of exceedance probability (Pr(STinteraction > 0)) of spatio-temporal interaction of case reporting, adjusted for varying testing intensity, by year and municipality, Denmark 2014-2022.

Fig 7

Discussion

In our study, we quantified the intensity of Legionnaires’ disease diagnostic testing in all Danish municipalities between 2014 and 2022 and showed that within Denmark there was substantial variation, both spatially and over time, with an overall increase from 275 tested persons per 100,000 inhabitants in 2014 to 620 tested persons per 100 000 inhabitants in 2022. Our estimation is based on comprehensive national test data of Legionella urinary antigen test, PCR for Legionella spp. and PCR for L. pneumophila for residents of Denmark.

Whereas the population of Denmark between 2014 and 2022 has increased with 4%, the number of persons tested for Legionella in a given year has increased with 141%. While diagnostic testing intensity may not be known, a similar pattern may take place in other countries. Many reports and studies signaling apparent increased Legionnaires’ disease incidence without considering the testing intensity will therefore not reliably reflect the underlying Legionnaires’ disease incidence. Whereas since the beginning of the century urinary antigen test availability drastically has changed the diagnostic landscape, we described during our study period a shift from urinary antigen test use to PCR use, further boosted by PCR lab capacity created during the COVID-19 pandemic. We considered in our study the total testing intensity and did not focus on the test characteristics of the urinary antigen and PCR tests, but these are also key to understand the yield of the tests and thus the resulting reporting incidence.

Over half of the variance in relative testing intensity is found to be spatially structured, with strong homogeneity within provincial boundaries. We expect this spatial structure to be attributable to the influence of clinical laboratories on diagnostic testing although assessing this was outside the scope of this study and would require sufficiently detailed information about the dynamic landscape of clinical laboratories’ action radii.

We also quantified the positive causal effect of diagnostic testing intensity on the case reporting incidence under the mandatory notification surveillance system. We found evidence for a threshold of yearly diagnostic testing intensity of slightly over 1% of the overall population, above which the disease detection does not increase anymore. This reflects a potential optimal level of diagnostic testing from a disease surveillance perspective, but is also relevant for clinical practice. This relationship may hold beyond Denmark, although comparative studies in other countries, as well as studies extending the scope to test type specific effects, seasonality, etc. would be required to ascertain this and could provide further insight.

Finally, we estimated the yearly municipal age-and sex-standardised case reporting, adjusted for the varying level of testing intensity, which we believe is a direct and better estimate of the underlying Legionnaires’ disease incidence than the unadjusted estimate. We justified this based on the assumption that the diagnostic testing intensity for Legionnaires’ disease depends on the overall community acquired pneumonia incidence, including by non-Legionella infections. We assume so due to the non-specificity of the Legionnaires’ disease clinical presentation, the higher volume of Legionella testing and CAP compared to Legionella infections, and the observed similarity in seasonality between diagnostic Legionella testing and CAP. We believe that may cause, in the presence of underascertainment, an indirect effect of no interest in our surveillance data between location (municipality) and time (year) on disease reporting.

A strength of our study is that the incidences are calculated at municipal level with appropriate partial pooling through hierarchical spatio-temporal models to address instability of small area estimates due to randomness. Our estimates range from 1.4 to 12.0 per 100 000 inhabitants across municipalities. A number of studies have reported national incidences. Examples are 1.2 cases per 100,000 in USA in 2023 [30], 3.06 in Canada in 2015–2019 [18], 3.9 in New Zealand in 2010–2020 [65], and 5.6 in Switzerland in 2020, with the canton Ticino having reached up to 14.3 cases/100 000 [13,66]. The notification rates are strongly year dependent, with most studies explicitly reporting increasing rates in the last 20 years. Also, in the EU/EEA, the annual age-standardized notification rate has increased over the last decade, from 1.1 in 2013 to 2.7 in 2023, with significant intercountry variation: several countries registered under 0.5 cases/100,000, while Slovenia registered in 2019 a peak national rate of 8.4 / 100,000 [11].

Our Bayesian approach allowed us to estimate exceedance (and deficit) probabilities. This way, we identified municipalities and years with a high probability of excess Legionnaires’ disease incidence, as well as units where very likely excess space-time interaction was at least partially indicative for increased environmental contamination or outbreak conditions. A recent study describes the advantages and superiority of Bayesian methods, including for the identification of outbreak areas [64]. Increasing the temporal resolution of the analysis, e.g., to monthly (and accounting for seasonality), could become the basis for future routine municipal-level incidence monitoring and outbreak detection or validation.

Our model identified Odense (Fyn) in 2015 as the only spot where the space-time interaction was with over 95% probability beyond the expected. This coincides with an outbreak of Knoxville ST9, as described by the public health authorities [67]. Kolding and Odense were the municipalities with high risk of Legionnaires’ disease over several years, and merit further comparative study of conditions in the natural environment (e.g., microclimate, soil or waterreservoirs), built environment (e.g., prevalence of water utility structures and cooling towers), behaviour (e.g., use of airconditioning, misting devices, spa pools or other man-made water systems), or bacterial strains endemic in the area (e.g., species, serogroup, MAb type, sequence type), possibly contrasting with municipalities where very low incidence are found.

Apart from Odense, also in Randers an increased case reporting had triggered attention of public health authorities in the past years. Randers is, as only area, clearly highlighted in the spatially unstructured effect (S16 Fig 19 in S1 Appendix). The area shows over 80% exceedance probability for the spatio-temporal interaction (Fig 7). The latter is also true for the following areas, mostly in one of the years: Koebenhavn, Frederiksberg, Gladsaxe, Roedovre, Hoersholm, Helsingoer, Aarhus, Norddjurs, Randers, Favrskov, Roskilde, Vejle, Aabenraa.

As the total case count included travel-associated cases with non-local exposure locations, we have tested the sensitivity of our results by excluding these. The exceedance probabilities for the relative case reporting and for the spatio-temporal interaction, after exclusion of travel-associated cases, are mapped in the Supplementary Information (S20 c Fig 25-27 in S1 Appendix). The results, e.g., the detection of Odense as cluster in 2015, remain consistent with our main conclusions.

Our study has also limitations, some of which relate to the data. The surveillance case definition of Legionnaires’ disease aims to capture in-healthcare-tested disease. We can distinguish two non-diagnostic pathways. A proportion of legionella-caused pneumonia may not present at clinical care. However, in a country with good access to healthcare, pneumonia cases (contrary to legionellosis) not presenting at primary or secondary care are expected to be infrequent. Another proportion of legionella-caused pneumonia may present at clinical care but may not receive a Legionnaires’ disease test. Our hierarchical model allows -in principle-, through partial pooling, to mutually learn between areas with higher testing and areas with lower testing, but this learning is not without limitations and compounding with measurement error due to sensitivity and specificity of the tests against different Legionella strains. Also related to data, we only used one data source to determine the location of cases, resulting in a small number of missing cases for the modeling. As these were evenly distributed, we do not believe this affects our conclusions.

Important limitations are related to the modelling assumptions. A first important caveat is that by adjusting for testing intensity, we may induce collider bias. Adjusting for an effect (Leg-tested) of a collider (Pneumonia), has the effect of partially adjusting for the collider itself, namely partially opening the biasing path (S1 Fig 2 in S1 Appendix). Simulation studies could be conceived to assess quantitatively the potential impact of such bias on the strength of our conclusions. We suggest that, awaiting such analyses, Danish public health authorities that wish to formulate public health action, compare our results with the total effect of the unadjusted model (S18 and 19 in S1 Appendix). We propose to be particularly cautious for those regions where this sensitivity analysis reveals a large discrepancy, considering that the unbiased direct effect is expected to lay between both model outputs (S20 b in S1 Appendix). We nevertheless believe that adjusting for the tested population is a necessary part of any advanced incidence estimation at population level. Our DAG also makes the strong assumption that there is no unmeasured confounding, e.g., by physician’s awareness, being a common cause of both the Legionella diagnostic testing intensity and the Legionnaires’ disease reporting (S1 Fig 3 in S1 Appendix). It is very plausible that there are such factors, for example if local or regional media coverage raises awareness among physicians, which will likely influence both the testing intensity and the reporting of cases.

Another potentially biasing factor to carefully consider in future studies is urbanization degree, which may be related both to exposure risk (e.g., density of cooling towers) and to the probability of diagnosis given being tested positive.

Furthermore, the acyclic nature of a DAG does not allow for plausible circular causation between case reporting and testing. Even in our suggested alternative DAG, with physician’s awareness as unmeasured confounder, we do not capture that reporting of cases may trigger increased testing, followed by even higher case reporting. Although we choose here a static cross-sectional spatio-temporal modeling framework, we modeled the observed data of diagnosed and reported Legionnaires’ disease explicitly recognizing the unobserved true disease incidence state.

To complement our study approach, and address the above drawbacks, we suggest that future studies employ dynamic state space models to estimate the evolving latent but hidden disease process, separately from the observation time series. Future studies may also explore the use of measurement error models, to account for sensitivity and specificity of the tests, related to test type (e.g., PCR L.pneumophila vs Legionella spp.), sample quality (e.g., lower vs upper respiratory samples), and prevalent bacterial strains (e.g., species, serogroup, sequence types). Similarly, future models may distinguish settings of infection, being travel-associated, community-acquired, or hospital-acquired.

For countries without a centralized national laboratory database, to do a similar study as ours would require the identification of other data sources. Alternatively, well designed probability sampling surveys from hospitals and their clinical laboratories may be performed. This would come with additional modelling challenges and corresponding assumptions for interpolation towards areal data. However, although the results obtained are specific to the Danish context, the generic data requirements and modelling assumptions are expected to be similar for a different context.

Conclusions

Despite limitations and possible bias, our study of testing-adjusted case reporting suggests that no substantial increase in Legionnaires’ disease has occurred during the nine-year study period. Instead, the case ascertainment by physicians has improved considerably through increased Legionella testing, particularly among elderly patients.

Our assessment of the Legionnaires’ disease testing intensity in Denmark shows major spatio-temporal variation across the country. We also quantified the positive effect of testing intensity on Legionnaires’ disease reporting and found a threshold of annually testing slightly over 1% of the population above which the yield of new cases does not further improve. Studies in other countries would be useful to assess the generalizability of these findings. Finally, we obtained testing-adjusted estimates of the spatio-temporal variation of Legionnaires’ disease over the Danish territory.

Our estimates and their uncertainty, given the model and the data, give physicians a potential benchmark about the diagnostic behavior at municipality level. Furthermore, public health authorities could differentiate and target diagnostic guidance, taking into consideration the actual diagnostic testing intensity and case detection. The authorities can also better direct resources for environmental research of areas with exceptionally high or low testing-adjusted disease incidence. Therefore, we believe our enhanced surveillance study results give important clues to improve diagnostic testing guidance and research into risk factors of Legionnaires’ disease, and ultimately to improve Legionnaires’ disease prevention and control.

Supporting information

S1 Appendix. Contains contextual data, extended methods and model information, and supplementary results.

(PDF)

pone.0346580.s001.pdf (11.3MB, pdf)

Acknowledgments

We are grateful to the Departments of Clinical Microbiology, Denmark, for their contribution to the national surveillance and the Danish Microbiology Database project (MiBa), and the staff of Statens Serum Institut who curate the MiBa register data. Our gratitude goes also to the clinicians who notified cases of Legionnaires’ disease to the Statens Serum Institut. We thank Miguel Hernán for the helpful discussion on the causal diagram and Olivier Cecchi for support with querying OpenStreetMap.

**Disclaimer: The views and opinions expressed herein are the authors’ own and do not necessarily state or reflect those of ECDC. ECDC is not responsible for the data and information collation and analysis and cannot be held liable for conclusions or opinions drawn.

Data Availability

Observed counts at province level of tested persons, cases and population are provided in the Tables 1 and 2 of the manuscript and Tables 1 to 4 of the supplementary material S4-S6. In the supplementary material S21-S24 we provide tables with the values of the estimates as shown in Figures 2 and 4 of the manuscript. Demographic and map data, along with computing code, are available at GitHub (https://github.com/erobesyn/dk_testing_reporting) and Zenodo (https://doi.org/10.5281/zenodo.15238532). Additional data from the Danish Microbiology Database (MiBa) and from the Epidemiological Surveillance System of Denmark cannot be shared publicly because they are owned by a third party (Departments of Clinical Microbiology and Statens Serum Institut). Data are available from Statens Serum Institut (contact via serum@ssi.dk, https://en.ssi.dk/about-us/information-about-processing-of-personal-data) for researchers who meet the criteria for access to confidential data.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Fraser DW, Tsai TR, Orenstein W, Parkin WE, Beecham HJ, Sharrar RG, et al. Legionnaires’ disease: description of an epidemic of pneumonia. N Engl J Med. 1977;297(22):1189–97. doi: 10.1056/NEJM197712012972201 [DOI] [PubMed] [Google Scholar]
  • 2.Graham FF, Finn N, White P, Hales S, Baker MG. Global Perspective of Legionella Infection in Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Observational Studies. Int J Environ Res Public Health. 2022;19(3):1907. doi: 10.3390/ijerph19031907 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Jordi R, Camille A, Alfonsina R, Sophie J. Severe Legionnaires’ disease. Ann Intens Care. 2024;14:51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23(16):17–00454. doi: 10.2807/1560-7917.ES.2018.23.16.17-00454 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Baker-Goering M, Roy K, Edens C, Collier S. Economic burden of Legionnaires’ disease, United States, 2014. Emerg Infect Dis. 2021;27(1):255–7. doi: 10.3201/eid2701.191198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Beauté J, Robesyn E, de Jong B, European Legionnaires’ Disease Surveillance Network. Legionnaires’ disease in Europe: all quiet on the eastern front? Eur Respir J. 2013;42(6):1454–8. doi: 10.1183/09031936.00089113 [DOI] [PubMed] [Google Scholar]
  • 7.European Commission. Commission Implementing Decision (EU) 2018 945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. Official Journal of the European Union. OJ L 170, 672018. 2018. p. 1–74. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945
  • 8.European Commission. Commission Decision 2002 253 EC of 19 March 2002 laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119 98 EC of the European Parliament and of the Council. OJ L 86, 342002. 2002. p. 44–62. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32002D0253
  • 9.Statens Serum Insitut (SSI), Denmark. EPI-NEWS - 2015, No 44. Legionella pneumonia. 2014. Available at: https://en.ssi.dk/news/epi-news/2015
  • 10.Statens Serum Institut (SSI), Denmark. Annual surveillance reports, Denmark. Legionnaires disease in Denmark 2023. 2024. Available at: https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/annual-reports-on-disease-incidence/l/legionnaires-disease-in-denmark-2023
  • 11.European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. Legionnaires’ disease, all cases, age-standardised rate 2023. 2025. Available at: https://atlas.ecdc.europa.eu/public/index.aspx
  • 12.Campese C, Jarraud S, Sommen C, Maine C, Che D. Legionnaires’ disease in France: sensitivity of the mandatory notification has improved over the last decade. Epidemiol Infect. 2013;141(12):2644–9. doi: 10.1017/S0950268813000502 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Fischer FB, Saucy A, Vienneau D, Hattendorf J, Fanderl J, de Hoogh K, et al. Impacts of weather and air pollution on Legionnaires’ disease in Switzerland: A national case-crossover study. Environ Res. 2023;233:116327. doi: 10.1016/j.envres.2023.116327 [DOI] [PubMed] [Google Scholar]
  • 14.Rudbeck M, Jepsen MR, Sonne IB, Uldum SA, Viskum S, Mølbak K. Geographical variation of sporadic Legionnaires’ disease analysed in a grid model. Epidemiol Infect. 2010;138(1):9–14. doi: 10.1017/S0950268809990185 [DOI] [PubMed] [Google Scholar]
  • 15.Cassell K, Thomas-Lopez D, Kjelsø C, Uldum S. Provincial trends in Legionnaires’ disease are not explained by population structure in Denmark, 2015 to 2018. Euro Surveill. 2021;26(25):2000036. doi: 10.2807/1560-7917.ES.2021.26.25.2000036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Uldum SA, Schjoldager LG, Baig S, Cassell K. A Tale of Four Danish Cities: Legionella pneumophila Diversity in Domestic Hot Water and Spatial Variations in Disease Incidence. Int J Environ Res Public Health. 2022;19(5):2530. doi: 10.3390/ijerph19052530 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl. 2002;36:20s–7s. doi: 10.1183/09031936.02.00702002 [DOI] [PubMed] [Google Scholar]
  • 18.McMullen CKM, Dougherty B, Medeiros DT, Yasvinski G, Sharma D, Thomas MK. Estimating the burden of illness caused by domestic waterborne Legionnaires’ disease in Canada: 2015-2019. Epidemiol Infect. 2024;152:e18. doi: 10.1017/s0950268824000013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yu VL. Legionnaires’ disease: seek and ye shall find. Cleve Clin J Med. 2001;68(4):318–22. doi: 10.3949/ccjm.68.4.318 [DOI] [PubMed] [Google Scholar]
  • 20.Buchholz U, Jahn HJ, Brodhun B, Lehfeld AS, Lewandowsky MM, Reber F, et al. Source attribution of community-acquired cases of Legionnaires’ disease-results from the German LeTriWa study; Berlin, 2016-2019. PLoS One. 2020;15(11):e0241724. doi: 10.1371/journal.pone.0241724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cunha BA, Cunha CB. Legionnaire’s Disease and its Mimics: A Clinical Perspective. Infect Dis Clin North Am. 2017;31(1):95–109. doi: 10.1016/j.idc.2016.10.008 [DOI] [PubMed] [Google Scholar]
  • 22.Chahin A, Opal SM. Severe Pneumonia Caused by Legionella pneumophila: Differential Diagnosis and Therapeutic Considerations. Infect Dis Clin North Am. 2017;31(1):111–21. doi: 10.1016/j.idc.2016.10.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Phin N, Parry-Ford F, Harrison T, Stagg HR, Zhang N, Kumar K, et al. Epidemiology and clinical management of Legionnaires’ disease. Lancet Infect Dis. 2014;14(10):1011–21. doi: 10.1016/S1473-3099(14)70713-3 [DOI] [PubMed] [Google Scholar]
  • 24.Ha R, Heilmann A, Lother SA, Turenne C, Alexander D, Keynan Y, et al. The Adequacy of Current Legionnaires’ Disease Diagnostic Practices in Capturing the Epidemiology of Clinically Relevant Legionella: A Scoping Review. Pathogens. 2024;13(10):857. doi: 10.3390/pathogens13100857 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200(7):e45–67. doi: 10.1164/rccm.201908-1581ST [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Götz H, Lindback J, Ripa T, Arneborn M, Ramsted K, Ekdahl K. Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods? Scand J Infect Dis. 2002;34(1):28–34. doi: 10.1080/00365540110077001 [DOI] [PubMed] [Google Scholar]
  • 27.Veličko I, Ploner A, Sparén P, Herrmann B, Marions L, Kühlmann-Berenzon S. Changes in the Trend of Sexually Acquired Chlamydia Infections in Sweden and the Role of Testing: A Time Series Analysis. Sex Transm Dis. 2021;48(5):329–34. doi: 10.1097/OLQ.0000000000001318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Engebretsen S, Aldrin M. Effect of testing criteria for infectious disease surveillance: The case of COVID-19 in Norway. PLoS One. 2024;19(8):e0308978. doi: 10.1371/journal.pone.0308978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Euser SM, Bruin JP, Mooi-Kokenberg EA, Peeters M, Verbakel H, Yzerman EP, et al. Diagnostic testing for Legionnaires’ disease in the Netherlands between 2007 and 2009: a possible cause for the decline in reported Legionnaires’ disease patients. Eur J Clin Microbiol Infect Dis. 2012;31(8):1969–74. doi: 10.1007/s10096-011-1528-z [DOI] [PubMed] [Google Scholar]
  • 30.Moffa MA, Rock C, Galiatsatos P, Gamage SD, Schwab KJ, Exum NG. Legionellosis on the rise: A scoping review of sporadic, community-acquired incidence in the United States. Epidemiology and Infection. 2023;151:e133. doi: 10.1017/S0950268823001206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Rota MC, Ancona FD, Cavallero GM, Bagnato B, Nacca G, Serra R. Disponibilita di tecniche di laboratorio per la diagnosieziologica delle infezioni delle basse vie respiratorie negli ospedali italiani. Ann Ig. 2007;19:509–17. [PubMed] [Google Scholar]
  • 32.Roberts ME, Macfarlane JT, George RC, Harrison TG. Microbiology investigations in community acquired pneumonia--most laboratories in England and Wales do not offer all those recommended in the British Thoracic Society guideline. J Infect. 2008;56(4):291–4. doi: 10.1016/j.jinf.2008.02.002 [DOI] [PubMed] [Google Scholar]
  • 33.Garrison LE, Shaw KMS, McCollum JT, Dexter C, Vagnone PMS, Thompson JH, et al. On-site availability of Legionella testing in acute care hospitals, United States. Infect Control Hosp Epidemiol. 2014;35(7):898–900. doi: 10.1086/676871 [DOI] [PubMed] [Google Scholar]
  • 34.Fischer FB, Deml MJ, Mäusezahl D. Legionnaires’ disease - a qualitative study on Swiss physicians’ approaches to the diagnosis and treatment of community-acquired pneumonia. Swiss Med Wkly. 2022;152(17–18). doi: 10.4414/smw.2022.w30157 [DOI] [PubMed] [Google Scholar]
  • 35.Allgaier J, Lagu T, Haessler S, Imrey PB, Deshpande A, Guo N, et al. Risk Factors, Management, and Outcomes of Legionella Pneumonia in a Large, Nationally Representative Sample. Chest. 2021;159(5):1782–92. doi: 10.1016/j.chest.2020.12.013 [DOI] [PubMed] [Google Scholar]
  • 36.Helbig JH, Uldum SA, Lück PC, Harrison TG. Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J Med Microbiol. 2001;50(6):509–16. doi: 10.1099/0022-1317-50-6-509 [DOI] [PubMed] [Google Scholar]
  • 37.Svarrer CW, Lück C, Elverdal PL, Uldum SA. Immunochromatic kits Xpect Legionella and BinaxNOW Legionella for detection of Legionella pneumophila urinary antigen have low sensitivities for the diagnosis of Legionnaires’ disease. J Med Microbiol. 2012;61(Pt 2):213–7. doi: 10.1099/jmm.0.035014-0 [DOI] [PubMed] [Google Scholar]
  • 38.Statens Serum Institut (SSI), Denmark. Annual surveillance reports, Denmark. Legionnaires disease in Denmark 2021. 2022. Available at: https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/annual-reports-on-disease-incidence/l/legionnaires-disease-in-denmark-2021;.
  • 39.Ricci ML, Grottola A, Fregni Serpini G, Bella A, Rota MC, Frascaro F, et al. Improvement of Legionnaires’ disease diagnosis using real-time PCR assay: a retrospective analysis, Italy, 2010 to 2015. Euro Surveill. 2018;23(50). doi: 10.2807/1560-7917.ES.2018.23.50.1800032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Viasus D, Gaia V, Manzur-Barbur C, Carratalà J. Legionnaires’ disease: update on diagnosis and treatment. Infect Dis Ther. 2022;11(3):973–86. doi: 10.1007/s40121-022-00635-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Woodhead M. Community-acquired pneumonia guidelines: much guidance, but not much evidence. Eur Respir J. 2002;20(1):1–3. doi: 10.1183/09031936.02.01042002 [DOI] [PubMed] [Google Scholar]
  • 42.Campese C, Bitar D, Jarraud S, Maine C, Forey F, Etienne J, et al. Progress in the surveillance and control of Legionella infection in France, 1998-2008. Int J Infect Dis. 2011;15(1):e30-7. doi: 10.1016/j.ijid.2010.09.007 [DOI] [PubMed] [Google Scholar]
  • 43.European Centre for Disease Prevention and Control (ECDC), Coronavirus disease 2019 data Reporting Protocol, The European Surveillance System. 2023. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-Reporting-Protocol-v64.pdf
  • 44.Zucs P, Beaute J, Palm D, Spiteri G. Focus, vigilance, resilience: towards stronger infectious disease surveillance, threat detection and response in the EU/EEA. Euro Surveill. 2024;29(34). doi: 10.2807/1560-7917.ES.2024.29.34.2400066 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Beauté J, Adlhoch C, Bundle N, Melidou A, Spiteri G. Testing indicators to monitor the COVID-19 pandemic. Lancet Infect Dis. 2021;21(10):1344–5. doi: 10.1016/S1473-3099(21)00461-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Hernán M, Robins J. Causal Inference: What If. Boca Raton: Chapman and Hall/CRC; 2020. Available from: https://static1.squarespace.com/static/675db8b0dd37046447128f5f/t/677676888e31cc50c2c33877/1735816881944/hernanrobins_WhatIf_2jan25.pdf [Google Scholar]
  • 47.McElreath R. Statistical rethinking: A bayesian course with examples in R and Stan. 2nd ed. Chapman and Hall/CRC; 2020. 10.1201/9780429029608 [DOI] [Google Scholar]
  • 48.Buchholz U, Altmann D, Brodhun B. Differential Seasonality of Legionnaires’ Disease by Exposure Category. Int J Environ Res Public Health. 2020;17(9):3049. doi: 10.3390/ijerph17093049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Murdoch KM, Mitra B, Lambert S, Erbas B. What is the seasonal distribution of community acquired pneumonia over time? A systematic review. Australas Emerg Nurs J. 2014;17(1):30–42. doi: 10.1016/j.aenj.2013.12.002 [DOI] [PubMed] [Google Scholar]
  • 50.Voldstedlund M, Haarh M, Mølbak K, the MiBa Board of Representatives. The Danish Microbiology Database (MiBa) 2010 to 2013. Eurosurveillance. 2014;19(1):20667. doi: 10.2807/1560-7917.ES2014.19.1.20667 [DOI] [PubMed] [Google Scholar]
  • 51.Schønning K, Dessau RB, Jensen TG, Thorsen NM, Wiuff C, Nielsen L, et al. Electronic reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national preparedness and control of COVID-19 in Denmark. APMIS. 2021;129(7):438–51. doi: 10.1111/apm.13140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Statens Serum Insitut (SSI), Denmark. Danish Microbiology Database (MiBa). 2024. Available at: https://mibaen.ssi.dk/miba
  • 53.Statens Serum Insitut (SSI), Denmark. Mandatory notification systems. 2025. Available at: https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/mandatory-notification-systems
  • 54.Statens Serum Insitut (SSI) Denmark. Notice regarding the processing of personal data at Statens Serum Institut. 2025. Available at: https://en.ssi.dk/about-us/information-about-processing-of-personal-data
  • 55.Statistics Denmark. Population data. 2024. Available at: https://www.statbank.dk/10021
  • 56.Lawson AB. Using R for Bayesian Spatial and Spatio-Temporal Health Modeling. Chapman and Hall/CRC; 2021. [Google Scholar]
  • 57.Watanabe S. Asymptotic equivalence of Bayes cross validation and widely applicable information criterion in singular learning theory. J Mach Learn Res. 2010;11:3571–94. [Google Scholar]
  • 58.Rue H, Martino S, Chopin N. Approximate Bayesian Inference for Latent Gaussian models by using Integrated Nested Laplace Approximations. J R Stat Soc Series B Stat Methodol. 2009;71(2):319–92. doi: 10.1111/j.1467-9868.2008.00700.x [DOI] [Google Scholar]
  • 59.R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2024. Available at: https://www.R-project.org/ [Google Scholar]
  • 60.Lindgren F, Rue H. Bayesian Spatial Modelling with R-INLA. J Stat Softw. 2015;63(19):1–25. [Google Scholar]
  • 61.Besag J, York J, Mollié A. Bayesian image restoration, with two applications in spatial statistics. Ann Inst Stat Math. 1991;43(1):1–20. doi: 10.1007/bf00116466 [DOI] [Google Scholar]
  • 62.Riebler A, Sørbye SH, Simpson D, Rue H. An intuitive Bayesian spatial model for disease mapping that accounts for scaling. Stat Methods Med Res. 2016;25(4):1145–65. doi: 10.1177/0962280216660421 [DOI] [PubMed] [Google Scholar]
  • 63.Knorr-Held L. Bayesian modelling of inseparable space-time variation in disease risk. Stat Med. 2000;19(17–18):2555–67. doi: 10.1002/1097-0258(20000915/30)19:17/18<2555::aid-sim587>3.0.co;2-# [DOI] [PubMed] [Google Scholar]
  • 64.Rotejanaprasert C, Chinpong K, Lawson AB, Chienwichai P, Maude RJ. Evaluation and comparison of spatial cluster detection methods for improved decision making of disease surveillance: a case study of national dengue surveillance in Thailand. BMC Med Res Methodol. 2024;24(1):14. doi: 10.1186/s12874-023-02135-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Graham FF, Harte D, Zhang J, Fyfe C, Baker MG. Increased incidence of legionellosis after improved diagnostic methods, New Zealand, 2000-2020. Emerg Infect Dis. 2023;29(6):1173–82. doi: 10.3201/eid2906.221598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Fischer FB, Mäusezahl D, Wymann MN. Temporal trends in legionellosis national notification data and the effect of COVID-19, Switzerland, 2000-2020. Int J Hyg Environ Health. 2023;247:113970. doi: 10.1016/j.ijheh.2022.113970 [DOI] [PubMed] [Google Scholar]
  • 67.Statens Serum Insitut (SSI), Denmark. EPI-NEWS - 2016, No 42/43. Legionella pneumonia. 2015. Available at: https://en.ssi.dk/news/epi-news/2016

Decision Letter 0

Marta Palusinska-Szysz

13 Oct 2025

Dear Dr. Robesyn,

Please submit your revised manuscript by Nov 27 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols....

We look forward to receiving your revised manuscript.

Kind regards,

Marta Palusinska-Szysz

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that Figures 2, 4, 5, 6, and 7 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (a) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (b) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figures 2, 4, 5, 6, and 7 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an ""Other"" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

3. Please ensure that you refer to Figures 5, 6, and 7 in your text as, if accepted, production will need this reference to link the reader to the figures.

4. Please upload a copy of Figures 8 and 9, to which you refer in your text on pages 19 and 20. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

5. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set.

Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.

Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data) and in the following article: http://www.bmj.com/content/340/bmj.c181.long.

6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

**********

Reviewer #1: Robesyn et al. present an interesting paper considering heterogeneity in LD testing and case reporting in space/time in Denmark. The analysis is of interest and benefits from multiple national-level data sources. I have the below comments which I hope will strengthen the manuscript further:

Abstract:

- Please could you briefly define (perhaps in brackets after ‘Legionella Test’) what legionella tests you are including (i.e UAT and PCRs)

- ‘Conform a positive time effect’ does not seem a grammatically correct ending to this sentence - please improve

Introduction:

- Typo line 44: ‘unknown to WHAT extent’ not ‘which’ extent

- Reformulation proposal lines 45-48:

‘Despite the global occurrence [2], the clinical severity [3], the public health burden (mostly attributable to years of life lost [4, 5]), and the treatable and preventable

character of this waterborne respiratory disease, many low- and middle-income countries

have no effective surveillance in place.’

- Line 48: add ‘within’ after including

Methods:

- Lines 137-138 ‘Latent Legionnaires’ disease incidence’. We would not typically refer to LD as being ‘latent’ as we would for other communicable diseases like TB. I think ‘undiagnosed’ may be more appropriate for the presumed meaning behind the sentence. Please amend here and elsewhere in the manuscript where LD is referred to as latent.

- Have case definitions remained consistent throughout the study period? Are they amended in the context of LD outbreaks?

- Lines 143-144 should be ‘both’ not ‘either’.

Results:

- Were there changes in the proportion of probable/confirmed cases over time?

- Line 303-304 please can you explain the sentence 83% of all positive tested persons in the database. Does this mean that the reported number (2183) is only 83% of the number of cases identified via the MiBa? I thought in lines 167-169 you stated the difference between the number of cases from both sources were negligible?

- To aid understanding and readability I think a more formal definition of RRT would be helpful. What is it relative to? i.e. what number would give an RRT of 1? I have the same point for RRC.

- Figure 3(b) the graph appears to have a more natural transition point somewhere between 1100-1200 tested persons/100,000. What is the rationale behind identifying 1000 as the transition point? That appears to still be on the upward slant of the curve. I think this graph would benefit from being made significantly larger - my understanding is that this is one of the most significant findings in the paper.

- Line 369 has ‘case case’

Discussion:

- The continued change in UAT and PCR testing over time is very interesting and deserves more comment/explanation in the discussion.

- When describing the diagnostic testing intensity I think there should be some acknowledgement that this will depend to a certain degree on the underlying ‘true’ incidence of disease over time (i.e. if there are more cases in the population, then the curve of testing intensity against case reporting may appear different). An acknowledgement that this may differ in different times, in addition to different places, would be helpful.

- Line 542 typo: areal

Conclusion:

- The conclusion ‘no substantial increase in true LD has occurred during the nine-year study period’ is too strong given the described limitations in the discussion, and is discordant with how the findings are more cautiously presented throughout the rest of the manuscript. Suggest amending to ‘suggests that’ or ‘evidence in favour of’.

**********

what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.. Please note that Supporting Information files do not need this step.. Please note that Supporting Information files do not need this step.. Please note that Supporting Information files do not need this step.

PLoS One. 2026 Apr 17;21(4):e0346580. doi: 10.1371/journal.pone.0346580.r002

Author response to Decision Letter 1


3 Dec 2025

Dear Academic Editor,

We would like to thank you and the Reviewer for the valuable comments.

We submit a revised version of our manuscript, taking into account the points raised during the review process. We have carefully addressed the comments and reply below to each of them, clarifying also what was adapted in the manuscript.

Comments by Academic Editor:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

We have edited the manuscript according to PLOS ONE’s style requirements. Files were renamed as required. We numbered the tables and figures and uploaded them separately. Textual changes are reflected in the revision file labelled 'Revised Manuscript with Track Changes'.

2. We note that Figures 2, 4, 5, 6, and 7 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data.

We have replaced the basemap of the Danish municipalities with data adapted from OpenStreetMap, available under the Open Database License, and we have added this information in the map legend. Furthermore, we have inserted the following information in the Material and Methods section: “The basemap of the Danish municipalities was adapted from OpenStreetMap, available under the Open Database License (openstreetmap.org/copyright).”

3. Please ensure that you refer to Figures 5, 6, and 7 in your text as, if accepted, production will need this reference to link the reader to the figures.

We have inserted reference to Figure 5. We have replaced the reference to Figure 8 and 9 by Figure 6 and 7, respectively.

4. Please upload a copy of Figures 8 and 9, to which you refer in your text on pages 19 and 20. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

We have replaced the reference to Figures 8 and 9 by Figure 6 and 7, respectively.

5. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set.

We have reviewed the data shared through the manuscript, the supplementary information, and the repositories, considering the Data Policy and the guidance in the recommended article. The data provided are anonymized.

We provide observed data counts in Table 1 and 2 in the manuscript and Tables 1-4 in the Supplementary Information S4-S6. Further, in the Supplementary Information S21-S24 we provide extensive look-up tables with the exact values of the estimates as shown in the maps of the manuscript and further results from sensitivity analyses. Demographic and map data, along with computing code, are available at the GitHub and Zenodo repository. For access to additional data, we explain in the data availability statement how these can be requested.

6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited.

The reviewer did not include a recommendation to cite specific previously published works.

Comments by Reviewer #1

Robesyn et al. present an interesting paper considering heterogeneity in LD testing and case reporting in space/time in Denmark. The analysis is of interest and benefits from multiple national-level data sources. I have the below comments which I hope will strengthen the manuscript further:

We are grateful for the comments and acknowledge that addressing them has significantly improved the manuscript.

Abstract:

- Please could you briefly define (perhaps in brackets after ‘Legionella Test’) what legionella tests you are including (i.e. UAT and PCRs).

Thank you for highlighting this important aspect. We have inserted the test types as follows: “persons receiving at least one Legionella urinary antigen or PCR test per 100,000 inhabitants.”

- ‘Conform a positive time effect’ does not seem a grammatically correct ending to this sentence – please improve.

We have replaced this by “reflecting an upward trend.”

Introduction:

- Typo line 44: ‘unknown to WHAT extent’ not ‘which’ extent

We have replaced the word, both in the Introduction and in the Abstract.

- Reformulation proposal lines 45-48: ‘Despite the global occurrence [2], the clinical severity [3], the public health burden (mostly attributable to years of life lost [4, 5]), and the treatable and preventable character of this waterborne respiratory disease, many low- and middle-income countries have no effective surveillance in place.’

We agree that the suggested reformulation improves the readability and have adopted the proposal.

- Line 48: add ‘within’ after including

We have inserted the word.

Methods:

- Lines 137-138 ‘Latent Legionnaires’ disease incidence’. We would not typically refer to LD as being ‘latent’ as we would for other communicable diseases like TB. I think ‘undiagnosed’ may be more appropriate for the presumed meaning behind the sentence. Please amend here and elsewhere in the manuscript where LD is referred to as latent.

Indeed, the meaning of ‘latent’ in our manuscript does not refer to the infection status of an individual. Instead, it refers to the unmeasured or hidden disease generating process or true disease incidence in the population, which is our surveillance target of interest that we aim to estimate. To avoid confusion, we have replaced the word ‘latent’ by ‘true’ Legionnaires disease incidence. Similarly, we have also adapted the formulation of latent state in the

Discussion.

- Have case definitions remained consistent throughout the study period? Are they amended in the context of LD outbreaks?

The case definition of Legionnaires’ disease used in Denmark, including in the context of outbreaks, is based on the official EU surveillance case definition. Outbreak case definitions differ mainly by restriction in time, place and person, but not in their clinical and laboratory criteria. Throughout the study period there was one change in the EU case definition, namely in 2018. The 2002 definition, valid until 25/07/2018, defined both Legionnaires’ disease and Pontiac fever, but this has not affected our study data, which is focussed on Legionnaires’ disease only. In both versions, a positive urinary antigen test was considered a confirmatory case criterium, while a positive PCR test classified the case as probable. This distinction in case classification was not deemed relevant to our study and was therefore not used. We note here that a large proportion (around 30-40%) of the PCR-positive cases in Denmark are confirmed by culture.

We have inserted the 2002 definition as reference in the Introduction of our manuscript, for completeness. We added a clarification in the Methods section: “Cases fulfilled the EU case definition of confirmed or probable case. Throughout the study period, the EU case definition considered a positive urinary antigen test as a confirmed case criterium, and a positive PCR test as a probable case criterium, but this distinction in case classification was not deemed relevant to our study and was therefore not used.”

- Lines 143-144 should be ‘both’ not ‘either’.

Indeed, both may influence the reported case count. We have replaced the word.

Results:

- Were there changes in the proportion of probable/confirmed cases over time?

For this study, we did not collect the variable ‘case classification’ but we can provide relevant background. Per the case definition in use during the study period, the proportion of probable and confirmed cases is largely (but not only) defined by the test types used: a positive urinary antigen test or a culture with isolation of Legionella spp. contributes to the case classification ‘confirmed’, while a positive PCR test contributes to a case being labelled as ‘probable’. As the proportion of urinary antigen test decreased and the proportion of PCR increased over the study period, the proportion of ‘confirmed’ cases has decreased. However, the binary surveillance classification ‘confirmed/probable case’ does not capture sufficiently the complexity of the test sensitivity and specificity of the different tests for the variety of Legionella species and serogroups causing clinical Legionnaires’ disease. We describe the most salient changes in use of test types over time in the paragraph before table 1, and we refer for more detail to Table 3 in the Supplementary Information S6 where we report on the within-year test profiles of the tested persons.

- Line 303-304 please can you explain the sentence 83% of all positive tested persons in the database. Does this mean that the reported number (2183) is only 83% of the number of cases identified via the MiBa? I thought in lines 167-169 you stated the difference between the number of cases from both sources were negligible?

Thank you for the question. To explain the difference, we refer to three nodes in Figure 1: ‘Pos Leg-tested’ or people who have tested positive for a Legionella test, ‘Diagnosed LD’ or people who were found to have Legionnaires’ disease by their clinician, and ‘Reported LD’ or people who’s diagnosis was recorded in the surveillance database by the Department of Infection Epidemiology and Prevention, Statens Serum Institut.

There is a significant difference between the number of positive Legionella tested persons and diagnosed cases (for which the reasons are explained in the manuscript), but a negligible difference between the number of diagnosed cases and reported cases.

We understand that our statement about ‘automated electronic reporting of data from the national microbiological database’ was misleading and did not capture that there is still a verification of the diagnosis with the clinician. The automated ‘detection algorithm’ of positive tests on the national microbiological database does not lead to automated ‘case reporting’ in the surveillance system but to verification of the diagnosis with the clinician.

We have corrected our manuscript text: “However, this is assumed negligible in Denmark since 2014 due to an automated detection algorithm on the national microbiological database, whereby for each positive test, the diagnosis is verified with the clinician.”

- “To aid understanding and readability, I think a more formal definition of RRT would be helpful. What is it relative to? i.e. what number would give an RRT of 1? I have the same point for RRC.”

We agree that the link between the model equations in the Methods and the terminology in the Results section was not explicit enough. The value of one for the relative risk (RR) refers to testing intensity or case reporting as expected based on the intensity or reporting in the whole study area. We have now inserted in the Methods section a clarifying text, with more formal definitions:

“In the Results section, we call the relative risk from the two models, respectively, the ‘relative testing intensity (RRT)’ and the ‘relative case reporting (RRC)’, i.e. the multiplicative factor for a specific year and municipality as compared to the expected value. A value of two means that the testing intensity or case reporting was twice as large as expected from the overall intensity/reporting in the whole country.”

- Figure 3(b) the graph appears to have a more natural transition point somewhere between 1100-1200 tested persons/100,000. What is the rationale behind identifying 1000 as the transition point? That appears to still be on the upward slant of the curve.

We have been hesitant to make strong conclusions about the trend above a testing intensity above 1000 tested persons/100,000 taking into consideration the slightly lower point estimates beyond 1200 and the larger uncertainty interval (Fig 3, b and S14 Fig 17). We have edited the text to capture better the continued increase of the point estimate up to 1200:

“Further, we estimated that with increasing testing intensity, the relative case reporting (on log scale) increased (Fig 3, b and S14 Fig 17). The increasing relative case reporting is observed up to about 1000 to 1200 tested persons per 100 000 inhabitants, with relative case reporting of about 1.6 (log(RRC) = 0.5). At higher testing intensities, there is no further improvement in case reporting and there is larger uncertainty of the estimate.”

- I think this graph would benefit from being made significantly larger - my understanding is that this is one of the most significant findings in the paper.

We agree that Fig 3, b is an essential finding and we have increased its size. At this occasion, we have also made the caption of Fig 3 more accurate.

- Line 369 has ‘case case’

Thank you for noting.

Discussion:

- The continued change in UAT and PCR testing over time is very interesting and deserves more comment/explanation in the discussion.

We fully agree and have elaborated on this point in the Discussion as follows:

“Whereas the population of Denmark between 2014 and 2022 has increased with 4 %, the number of persons tested for Legionella in a given year has increased with 141%. While diagnostic testing intensity may not be known, a similar pattern may take place in other countries. Many reports and studies signalling apparent increased Legionnaires’ disease incidence without considering the testing intensity will therefore not reliably reflect true Legionnaires’ disease incidence.

Where since the beginning of the century urinary antigen test availability has drastically changed the diagnostic landscape, we described during our study period a shift from urinary antigen test use to PCR use, further boosted by PCR lab capacity created during the COVID-19 pandemic. We considered in our study the total testing intensity and did not focus on the test characteristics of the urinary antigen and PCR tests, but these are also key to understand the yield of the tests and thus the resulting reporting incidence.”

- When describing the diagnostic testing intensity I think there should be some acknowledgement that this will depend to a certain degree on the underlying ‘true’ incidence of disease over time (i.e. if there are more cases in the population, then the curve of testing intensity against case reporting may appear different). An acknowledgement that this may differ in different times, in addition to different places, would be helpful.

Indeed, in line with our DAG in Fig 1, the true disease will affect the testing intensity over time. We have reinforced the importance of the time dimension, in parallel to the spatial dimension, in the following way. Where we wrote “Even in our suggested alternative DAG, with physician’s awareness as unmeasured confounder, we do not capture that reporting of cases may trigger increased testing, followed by even higher case reporting.”, we have added “Such short as well as long changes over time may happen simultaneous to changes in true disease incidence, e.g. due to weather and climatic conditions, clearly making the inference of true disease incidence a major challenge.”

- Line 542 typo: areal

We believe the spelling is correct, referring to an area. Our modelling was based on counts in (administrative) area’s. When data were to come from hospitals, these counts would need to be attributed to a recruitment area to know the denominator for incidence calculation and modelling. We edited the sentence slightly to improve the structure.

Conclusion:

- The conclusion ‘no substantial increase in true LD has occurred during the nine-year study period’ is too strong given the described limitations in the discussion, and is discordant with how the findings are more cautiously presented throughout the rest of the manuscript. Suggest amending to ‘suggests that’ or ‘evidence in favour of’.

Thank yo

Attachment

Submitted filename: Response to Reviewers.docx

pone.0346580.s002.docx (39.7KB, docx)

Decision Letter 1

Marta Palusinska-Szysz

2 Feb 2026

Diagnostic testing intensity for Legionnaires’ disease: spatio-temporal assessment and its effect on surveillance case reporting, Denmark, 2014-2022

PLOS One

Dear Dr.  Robesyn,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 19 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols....

We look forward to receiving your revised manuscript.

Kind regards,

Marta Palusinska-Szysz

Academic Editor

PLOS One

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

Comments to the Author

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #2: Yes

**********

Reviewer #2: The study provides timely and important results for developing surveillance approaches to LD. The analysis uses an extensive national dataset of LD cases and diagnostic testing in Denmark. The modelling approach is novel and relevant to the field, the manuscript is generally well presented, and the figures and tables are clear. My comments mainly concern the robustness of the conclusions.

Major comments

• Throughout the manuscript, especially in the abstract and conclusions, the interpretation shifts from testing-adjusted reporting (as a proxy for underlying incidence) to statements about “true” LD incidence. Even with the cautious wording (“suggest”), this may be read as a claim about the underlying disease process rather than the surveillance process. The analysis does not account for all uncertainties in diagnostic/ascertainment (e.g., it includes only cases that enter the diagnostic pathway), and the manuscript notes that adjusting for testing intensity can introduce collider bias. A revision of the abstract and conclusions to focus on testing-adjusted reporting and to reflect these limitations will avoid misinterpretation.

• The manuscript interprets spatially structured and space–time interaction effects as municipality-level clustering and potentially local environmental conditions. However, travel-associated cases, assigned to the municipality of residence rather than the likely exposure location, are included. Some spatial patterns may therefore reflect non-local exposures, affecting how “local” risk patterns are interpreted. Clarifying the rationale for including travel-associated cases, or providing a sensitivity analysis excluding them, would make the conclusions more reliable.

• A relevant potential confounder that is not clearly addressed is urbanicity. Urbanicity may relate to both i) testing intensity and ii) exposure opportunities (e.g., higher density of cooling towers in urban areas). This could bias the estimated testing–case relationship and the interpretation of testing-adjusted spatial patterns.

Minor comments

• L116: The prevention of LD depends not only on diagnostic guidelines and surveillance, but also on effective risk management of pathogenic Legionella species in engineered water systems. Please revise to reflect this broader prevention context.

• L257: The manuscript describes the testing effect as linear, while the SI indicates the results come from a nonlinear RW1 smooth over binned testing intensity. Please clarify the model specification in the main text to avoid confusion.

• Figure 3 presents results on the logarithmic scale. For most readers, would it be easie to interpret on the arithmetic scale?

**********

what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #2: Yes: Émile SylvestreÉmile SylvestreÉmile SylvestreÉmile Sylvestre

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Apr 17;21(4):e0346580. doi: 10.1371/journal.pone.0346580.r004

Author response to Decision Letter 2


14 Mar 2026

Dear Academic Editor,

We thank the second reviewer for the highly relevant comments. We believe that addressing them has significantly improved our manuscript.

Please note that the attached document 'Response to reviewers_2' contains the figures pertaining to this reponse.

Reviewer:

The study provides timely and important results for developing surveillance approaches to LD. The analysis uses an extensive national dataset of LD cases and diagnostic testing in Denmark. The modelling approach is novel and relevant to the field, the manuscript is generally well presented, and the figures and tables are clear. My comments mainly concern the robustness of the conclusions.

Major comments

1. Throughout the manuscript, especially in the abstract and conclusions, the interpretation shifts from testing-adjusted reporting (as a proxy for underlying incidence) to statements about “true” LD incidence. Even with the cautious wording (“suggest”), this may be read as a claim about the underlying disease process rather than the surveillance process. The analysis does not account for all uncertainties in diagnostic/ascertainment (e.g., it includes only cases that enter the diagnostic pathway), and the manuscript notes that adjusting for testing intensity can introduce collider bias. A revision of the abstract and conclusions to focus on testing-adjusted reporting and to reflect these limitations will avoid misinterpretation.

We thank the reviewer for the thoughtful comment. We agree that the testing-adjusted reporting, our analysis outcome, is an imperfect proxy for the underlying incidence. Aspects like cases not presenting to healthcare, measurement error in the tests, dynamic interactions, unmeasured confounders, etc. are not accounted for, and we cannot exclude partial (i.e. depending on the strength of association between collider and descendant) collider bias. To avoid misinterpretation or overconfidence, we have removed ‘true’ where we refer to our work and meant latent or underlying incidence and adapted the wording in the abstract, the main text (original lines 127, 139, 148, 483, 579) and the conclusions.

Nevertheless, we do not want to obfuscate that one estimand of our surveillance study is indeed the underlying disease incidence, which -through our proxy- we tried to estimate to the best of our ability. We therefore feel it is needed to cautiously conclude on the underlying incidence or disease process, without suggesting it is ‘true’. The reasoning is similar to the argument that a causal analysis should, despite limitations, conclude on causal effects and not limit its conclusions to merely describing associations (Hernan, 2018). However, we have carefully avoided to refer to the underlying incidence or process in the Results section, and we refer in that section only to ‘testing-adjusted reporting’.

Reference: Hernán MA. Am J Public Health. 2018 May;108(5):616-619. doi: 10.2105/AJPH.2018.304337. Epub 2018 Mar 22. URL: https://pubmed.ncbi.nlm.nih.gov/29565659/

We are grateful for pointing at the limitation of the non-diagnostic path and we have inserted this aspect at the start of our limitations section. We take the opportunity to elaborate here a little further.

The surveillance case definition of Legionnaires’ disease indeed only aims to capture in-healthcare-tested disease. A proportion of legionella-caused pneumonia may not present at clinical care. However, in a country with good access to healthcare, pneumonia cases (contrary to legionellosis) not presenting at primary or secondary care are expected to be infrequent.

Another non-diagnostic pathway would be legionella-caused pneumonia presenting at healthcare but not receiving a Legionnaires’ disease test. Our hierarchical model allows -in principle-, through partial pooling, to mutually learn between areas with higher testing and areas with lower testing. This learning is not without limitations and future (simulation) studies may assess whether post-stratification, e.g. simulating a situation where all areas have very high testing, would provide better incidence estimates. Such studies could include measurement error models where test characteristics like sensitivity and specificity against different Legionella strains are taken into account.

In countries with generalised under-ascertainment, i.e. low testing in all or most areas, learning through partial pooling would be poor, and the non-diagnostic pathway would be an even more important limitation.

2. The manuscript interprets spatially structured and space–time interaction effects as municipality-level clustering and potentially local environmental conditions. However, travel-associated cases, assigned to the municipality of residence rather than the likely exposure location, are included. Some spatial patterns may therefore reflect non-local exposures, affecting how “local” risk patterns are interpreted. Clarifying the rationale for including travel-associated cases, or providing a sensitivity analysis excluding them, would make the conclusions more reliable.

Our primary estimand was the effect of testing intensity on the total Legionnaires’ disease reporting, the main indicator in many surveillance reports, and for that reason travel-associated cases were included. However, inferring local environmental risk from total case incidence may indeed be biased by the inclusion of travel-associated cases. To test the sensitivity of our results to this inclusion, we have now also made estimates excluding travel-associated cases and we have added this sensitivity analysis to the supplementary material. The estimated case reporting and the exceedance probabilities for both the relative case reporting and the spatio-temporal interaction are shown in S20 Fig 25-27, and at the end of this document. The results, e.g. the detection of Odense as cluster in 2015, remain consistent with our main conclusions. We have added this information also to the Discussion section.

3. A relevant potential confounder that is not clearly addressed is urbanicity. Urbanicity may relate to both i) testing intensity and ii) exposure opportunities (e.g., higher density of cooling towers in urban areas). This could bias the estimated testing–case relationship and the interpretation of testing-adjusted spatial patterns.

We agree that it is important to assess the potential biasing effect of urbanization degree on our estimates. Doing so on https://dagitty.net/, we found that adjustment for urbanization degree is only needed if we make the additional assumption that urbanization is related to the probability of being diagnosed, given being tested positive. Note that in the below graphs the arrow between Legionella infections and pneumonia is removed for illustrative purpose as in Figure 3 of Supplement S1, to highlight the relevant causal paths.

In the first graph below, where urbanization is influencing the presence of Legionella determinants (e.g. density of cooling towers) as well as the testing intensity (e.g. higher in cities), the path is blocked on Legionella determinants, whether or not we adjust for Legionella testing intensity.

[Figure in attached document]

In the alternative graph below, where the area determines the degree of urbanization, and the latter influences the testing intensity, we must adjust for urbanization to measure the direct path from municipality to reported cases (a). However, that is not needed anymore once we adjust for testing intensity (Leg-tested as white circle) (b).

[Figures in attached document]

Finally, when we consider that urbanization degree not only relates to testing intensity but also to the probability of being diagnosed, given being tested positive, then indeed bias is possible and adjustment for urbanization degree is needed.

[Figure in attached document]

We believe this may be a realistic assumption. At the time of our study this data was not available. We have mentioned this relevant factor in the Discussion, for consideration in future studies.

Minor comments

4. L116: The prevention of LD depends not only on diagnostic guidelines and surveillance, but also on effective risk management of pathogenic Legionella species in engineered water systems. Please revise to reflect this broader prevention context.

Thank you for the remark. We agree and have inserted this critical preventive element to the text.

5. L257: The manuscript describes the testing effect as linear, while the SI indicates the results come from a nonlinear RW1 smooth over binned testing intensity. Please clarify the model specification in the main text to avoid confusion.

Thank you for flagging this. We have corrected the notation and accompanying text.

6. Figure 3 presents results on the logarithmic scale. For most readers, would it be easier to interpret on the arithmetic scale?

Indeed, this will help the interpretation of our results. We have now plotted the relative testing intensity and the relative case reporting on the arithmetic scale.

[Figure in attached document]

Three Figures added to supplement S20, sensitivity analyses: relative case reporting and exceedance probabilities from data excluding travel-associated cases.

[Figures in attached document]

Attachment

Submitted filename: Response to reviewers_2.docx

pone.0346580.s003.docx (960.9KB, docx)

Decision Letter 2

Marta Palusinska-Szysz

22 Mar 2026

Diagnostic testing intensity for Legionnaires’ disease: spatio-temporal assessment and its effect on surveillance case reporting, Denmark, 2014-2022

PONE-D-25-22931R2

Dear Dr. Emmanuel Robesyn,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support....

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Marta Palusinska-Szysz

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Marta Palusinska-Szysz

PONE-D-25-22931R2

PLOS One

Dear Dr. Robesyn,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Marta Palusinska-Szysz

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Contains contextual data, extended methods and model information, and supplementary results.

    (PDF)

    pone.0346580.s001.pdf (11.3MB, pdf)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0346580.s002.docx (39.7KB, docx)
    Attachment

    Submitted filename: Response to reviewers_2.docx

    pone.0346580.s003.docx (960.9KB, docx)

    Data Availability Statement

    Observed counts at province level of tested persons, cases and population are provided in the Tables 1 and 2 of the manuscript and Tables 1 to 4 of the supplementary material S4-S6. In the supplementary material S21-S24 we provide tables with the values of the estimates as shown in Figures 2 and 4 of the manuscript. Demographic and map data, along with computing code, are available at GitHub (https://github.com/erobesyn/dk_testing_reporting) and Zenodo (https://doi.org/10.5281/zenodo.15238532). Additional data from the Danish Microbiology Database (MiBa) and from the Epidemiological Surveillance System of Denmark cannot be shared publicly because they are owned by a third party (Departments of Clinical Microbiology and Statens Serum Institut). Data are available from Statens Serum Institut (contact via serum@ssi.dk, https://en.ssi.dk/about-us/information-about-processing-of-personal-data) for researchers who meet the criteria for access to confidential data.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES